C
Claudia Morabito
Researcher at University of Messina
Publications - 12
Citations - 84
Claudia Morabito is an academic researcher from University of Messina. The author has contributed to research in topics: Medicine & Sacubitril, Valsartan. The author has an hindex of 3, co-authored 11 publications receiving 58 citations.
Papers
More filters
Journal ArticleDOI
Cardiovascular Risk in Psoriasis: Current State of the Art
Giuseppe Dattilo,Francesco Borgia,Claudio Guarneri,Matteo Casale,Roberto Bitto,Claudia Morabito,Salvatore Santo Signorelli,Niki Katsiki,Serafinello P Cannavò +8 more
TL;DR: This paper will try to provide answers to questions about the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, and the presence of Psoriatic Arthritis (PsA) as a predictor of increased CV mortality and morbidity in psoriatic patients in the light of the updated data of the literature.
Journal ArticleDOI
The existential suspension of the young-adult in times of liquid modernity. A differential analysis of identity uneasiness in precarious times
Ivan Formica,Monica Pellerone,Claudia Morabito,Nadia Barberis,Tiziana Ramaci,Antonio Di Giorgio,Giuseppe Mannino +6 more
TL;DR: In this paper, the authors investigated the relationship between personal and social identity, identifying possible similarities and differences between a group of Italian employed adults and a groups of unemployed adults, and found that having a permanent employment, an elevated self-esteem, and good ego-strength, and internal locus of control are predictive of the adult identity among employed subjects.
Journal ArticleDOI
Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study.
Matteo Casale,Michele Correale,Giulia Laterra,Vittoria Vaccaro,Claudia Morabito,Pasquale Crea,Salvatore Santo Signorelli,Niki Katsiki,Francesco Luzza,Cesare de Gregorio,Giuseppe Dattilo +10 more
TL;DR: Sacubitril/valsartan therapy for HFrEF may lead to significant clinical and functional improvements even in patients with ICD at greater arrhythmic risk, especially within the first 6 months of therapy.
Journal ArticleDOI
The thromboembolism in COVID-19: the unsolved problem.
Matteo Casale,Giuseppe Dattilo,Egidio Imbalzano,Marianna Gigliotti De Fazio,Claudia Morabito,Maurizio Mezzetti,Paolo Busacca,Salvatore Santo Signorelli,Natale Daniele Brunetti,Michele Correale +9 more
TL;DR: Despite a strong pathophysiological rationale, the evidences in literature are not enough to recommend an aggressive antithrombotic therapy in COVID- 19, however, it is opinion that an early use, even at the beginning of the disease, could improve the clinical course.
Journal ArticleDOI
Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.
Egle Corrado,Giuseppe Dattilo,Giuseppe Coppola,Claudia Morabito,Enrico Bonnì,Luca Zappia,Giuseppina Novo,Cesare de Gregorio +7 more
TL;DR: In this paper, the authors investigated clinical and functional effects in real-life patients with heart failure and reduced ejection fraction (HFrEF) receiving ARNI at a different cumulative dose.